Tandem Diabetes Care, Inc.
’s
TNDM
reported GAAP loss per share of 23 cents for the first quarter of 2022 was wider than the loss of 8 cents per share in the year-ago period. This figure also compared unfavorably with the Zacks Consensus Estimate of break-even earnings.
Revenues
Revenues in the quarter came in at $175.9 million, up 24.7% year over year and beating the Zacks Consensus Estimate by 4.4%. The strength in the top line was driven by growth in the company’s installed base and robust pump shipments, both in and outside the United States.
Quarter in Detail
Tandem Diabetes registered sales of $44.6 million outside the United States in the quarter under review, recording a 18.4% rise from first-quarter 2021. Total sales in the United States came in at $131.3 million, up 27% year over year.
Pump shipments outside the United States surged 8.4% to 9,437 pumps. Meanwhile, U.S. pump shipments jumped 12.1% year over year to 18,658 units.
Tandem Diabetes Care, Inc. Price, Consensus and EPS Surprise
Tandem Diabetes Care, Inc. price-consensus-eps-surprise-chart
|
Tandem Diabetes Care, Inc. Quote
The surge in pump shipments outside the United States resulted from a remarkable growth in the number of customers compared to the year-ago period. Meanwhile, pump shipments within the United States benefitted from increasing new and renewal customers.
Margins
Gross profit in the first quarter was $91.1 million, marking 24.3% year-over-year growth. Gross margin was 51.8%, indicating a contraction of 18 basis points (bps).
Selling, general and administrative expenses rose 25.1% to $73.3 million in the quarter under review. Research and development expenses also increased 84.6% to $33.2 million.
The company registered an operating loss of $15.3 million in the first quarter.
Financial Position
Tandem Diabetes exited the first quarter of 2022 with cash and cash equivalents, and short-term investments of $635.4 million compared with $623.8 million recorded at the end of 2021.
2022 Guidance
Tandem Diabetes has updated its financial guidance for 2022.
For the year, sales are projected in the range of $850-$865 million (up from the prior projection of $845-$860 million), indicating annual sales growth of 21% to 23%. The Zacks Consensus Estimate for 2022 revenues is pegged at $851.24 million.
Full-year sales guidance for the United States is in the range of $635-$645 million (up from the prior estimated $630-$640 million).
The company has maintained its full-year sales guidance for outside the United States at the band of $215-$220 million.
Our Take
Tandem Diabetes exited the first quarter with better-than-expected revenues. The company delivered record sales growth in and outside the United States. Robust pump shipments in the quarter resulted from an increase in the company’s installed base. The company witnessed strong customer retention in the first quarter, primarily driven by the impressive positive response from the Control-IQ technology. Continued adoption of the company’s t:slim X2 insulin pumps looks encouraging. The raised sales guidance for 2022 also instills investors’ confidence.
However, the company’s earnings missed the Zacks Consensus Estimate. Contraction of gross margin is discouraging. The company incurred an operating loss in the quarter, raising apprehension.
Zacks Rank and Key Picks
Tandem Diabetes currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks in the broader medical space that have announced quarterly results are
Alkermes plc
ALKS
,
Medpace Holdings, Inc.
MEDP
and
UnitedHealth Group Incorporated
UNH
.
Alkermes reported first-quarter 2022 adjusted EPS of 12 cents, which surpassed the Zacks Consensus Estimate of a penny. Revenues of $278.6 million outpaced the Zacks Consensus Estimate by 6.2%. It currently sports a Zacks Rank #1 (Strong Buy). You can see
the complete list of today’s Zacks #1 Rank stocks here.
Alkermes has an estimated long-term growth rate of 25.1%. ALKS’ earnings surpassed estimates in the trailing four quarters, the average surprise being 350.5%.
Medpace reported first-quarter 2022 adjusted EPS of $1.69, which surpassed the Zacks Consensus Estimate by 34.1%. Revenues of $330.9 million outpaced the Zacks Consensus Estimate by 1.1%. It currently has a Zacks Rank #2.
Medpace has a historical growth rate of 27.3%. MEDP’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.1%.
UnitedHealth, having a Zacks Rank #2, reported first-quarter 2022 adjusted EPS of $5.49, which beat the Zacks Consensus Estimate by 1.7%. Revenues of $80.1 billion outpaced the consensus mark by 1.9%.
UnitedHealth has an estimated long-term growth rate of 14.8%. UNH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.7%.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
